# Novo Parity Experimentation Plan

**Branch**: `ray/novo-parity-experiments`
**Date**: 2025-11-03
**Status**: ğŸ§ª Active experimentation | Full traceability required
**Goal**: Explore permutations to understand Novo's 86-antibody (59 spec / 27 nonspec) construction

---

## ğŸ¯ PRIMARY OBJECTIVE

**Test multiple hypotheses** for how Novo got from 116 â†’ 86 antibodies with 59/27 distribution.

**Ground truth**: We start with 116 ELISA-only antibodies (94 specific / 22 non-specific)
**Target**: 86 antibodies (59 specific / 27 non-specific)
**Constraint**: Cannot reach 27 non-specific without reclassification or importing antibodies

**Critical acceptance**: We likely won't match Novo exactly - this is exploratory!
**Primary SSOT**: The full 116-antibody ELISA-only set remains our main test set

---

## ğŸ“ FILE ORGANIZATION

### Directory Structure
```
experiments/novo_parity/
â”œâ”€â”€ scripts/              # Numbered experiment scripts
â”‚   â”œâ”€â”€ exp_01_baseline.py
â”‚   â”œâ”€â”€ exp_02_biology_qc.py
â”‚   â””â”€â”€ ...
â”œâ”€â”€ datasets/            # Generated test sets
â”‚   â”œâ”€â”€ jain_exp_01_baseline_86.csv
â”‚   â”œâ”€â”€ jain_exp_02_biology_qc_86.csv
â”‚   â””â”€â”€ ...
â”œâ”€â”€ results/             # Inference results & audit logs
â”‚   â”œâ”€â”€ exp_01_results.json
â”‚   â”œâ”€â”€ exp_01_confusion_matrix.txt
â”‚   â””â”€â”€ ...
â””â”€â”€ EXPERIMENTS_LOG.md   # Running log of all experiments
```

### Naming Conventions

**Scripts**: `exp_{N:02d}_{short_description}.py`
- Example: `exp_01_baseline.py`, `exp_02_biology_qc.py`

**Datasets**: `jain_exp_{N:02d}_{description}_{size}.csv`
- Example: `jain_exp_01_baseline_86.csv`

**Results**: `exp_{N:02d}_{metric}.{json|txt|csv}`
- Example: `exp_01_results.json`, `exp_01_confusion_matrix.txt`

**Audit logs**: `exp_{N:02d}_audit.json`
- Contains: script path, input files, removed IDs, reclassified IDs, timestamps

---

## ğŸ§ª EXPERIMENT REGISTRY

### Experiment 01: Baseline (No QC, Just Count)
**Status**: ğŸ“‹ Planned
**Hypothesis**: Verify starting numbers
**Method**: Load 116 ELISA-only, count distribution
**Expected**: 94 specific / 22 non-specific = 116 total
**Script**: `experiments/novo_parity/scripts/exp_01_baseline.py`
**Output**: `experiments/novo_parity/datasets/jain_exp_01_baseline_116.csv`
**Web validation**: N/A (sanity check)

---

### Experiment 02: Biology-First QC (Assistant's Method)
**Status**: ğŸ“‹ Planned
**Hypothesis**: Sequence/biophysics QC yields 66/20 split
**Method**:
  1. Remove VH/VL length outliers (|z|â‰¥2.5)
  2. Remove CDR-H3 pathologies (<5 or >26 aa, |z|â‰¥2.5)
  3. Remove charge extremes (|z|â‰¥2.5)
  4. Tiebreaker removal to reach 86 total

**Expected**: 66 specific / 20 non-specific = 86 total
**Removed IDs**:
  - cixutumumab (VH outlier)
  - muromonab (CDR-H3)
  - lenzilumab (charge)
  - 27 via tiebreaker

**Script**: `experiments/novo_parity/scripts/exp_02_biology_qc.py`
**Output**: `experiments/novo_parity/datasets/jain_exp_02_biology_qc_86.csv`
**Web validation**: TODO - search for clinical/biology issues with removed antibodies

---

### Experiment 03: Parity Shim (Reclassify 7)
**Status**: ğŸ“‹ Planned
**Hypothesis**: Starting from Exp02 (66/20), flip 7 ELISA=0 â†’ nonspec to hit 59/27
**Method**:
  1. Start with exp_02 dataset (86 antibodies, 66/20)
  2. Reclassify 7 specific â†’ non-specific (deterministic ranking)
  3. Keep same 86 antibodies

**Reclassified IDs** (from assistant's analysis):
  - ganitumab
  - gemtuzumab
  - panitumumab
  - tigatuzumab
  - girentuximab
  - efalizumab
  - zanolimumab

**Expected**: 59 specific / 27 non-specific = 86 total
**Script**: `experiments/novo_parity/scripts/exp_03_parity_shim.py`
**Output**: `experiments/novo_parity/datasets/jain_exp_03_parity_shim_86.csv`
**Web validation**: TODO - search each of the 7 for polyreactivity/clinical issues

---

### Experiment 04: Our Z-Score QC (24 Candidates)
**Status**: ğŸ“‹ Planned
**Hypothesis**: Remove our 24 QC candidates (z-score + known issues)
**Method**:
  1. Start with 116 ELISA-only
  2. Remove 24 QC candidates identified via z-scoring
  3. Results in 92 antibodies (73 spec / 19 nonspec)
  4. Need to handle the remaining gap

**Removed IDs** (24 total):
  - cixutumumab (VH outlier + nonspec)
  - dalotuzumab, robatumumab (nonspec with issues)
  - 21 specific with chimeric/discontinued/withdrawn/outliers

**Expected**: 92 antibodies (73 specific / 19 non-specific)
**Gap**: Still 6 antibodies away from 86, and wrong distribution
**Script**: `experiments/novo_parity/scripts/exp_04_zscore_qc.py`
**Output**: `experiments/novo_parity/datasets/jain_exp_04_zscore_qc_92.csv`
**Web validation**: TODO - verify chimeric/discontinued status

---

### Experiment 05: Reclass Then Remove (Our Hypothesis)
**Status**: ğŸ“‹ Planned
**Hypothesis**: Reclassify 5 ELISA=0 (with other flags) â†’ nonspec, THEN remove 30 specific
**Method**:
  1. Start with 116 ELISA-only (94 spec / 22 nonspec)
  2. Reclassify 5 of our 7 candidates (ELISA=0, totalâ‰¥3) â†’ non-specific
  3. Result: 89 spec / 27 nonspec = 116 total
  4. Remove 30 specific antibodies (21 QC candidates + 9 more)
  5. Final: 59 spec / 27 nonspec = 86 total

**Reclassification candidates** (pick 5 of 7):
  - bimagrumab (ELISA=0, total=4) â† Top pick
  - atezolizumab (ELISA=0, total=3)
  - eldelumab (ELISA=0, total=3)
  - glembatumumab (ELISA=0, total=3)
  - infliximab (ELISA=0, total=3)
  - rilotumumab (ELISA=0, total=3)
  - seribantumab (ELISA=0, total=3)

**Removed IDs** (30 total):
  - 21 from our QC list (z-score analysis)
  - 9 more specific (TBD - need to identify)

**Expected**: 59 specific / 27 non-specific = 86 total
**Script**: `experiments/novo_parity/scripts/exp_05_reclass_then_remove.py`
**Output**: `experiments/novo_parity/datasets/jain_exp_05_reclass_remove_86.csv`
**Web validation**: TODO - search 7 reclass candidates for polyreactivity/aggregation

---

### Experiment 06: ELISA Threshold â‰¥3 (Alternative Hypothesis)
**Status**: ğŸ“‹ Planned
**Hypothesis**: Novo used ELISAâ‰¥3 instead of â‰¥4 to define non-specific
**Method**:
  1. Start with full 137 antibodies
  2. Exclude mild (ELISA 1-2) instead of (ELISA 1-3)
  3. Count resulting distribution
  4. Apply QC to reach 86

**Expected**: More non-specific antibodies (possibly 27+)
**Script**: `experiments/novo_parity/scripts/exp_06_threshold_3.py`
**Output**: `experiments/novo_parity/datasets/jain_exp_06_threshold3_86.csv`
**Web validation**: Check Novo paper for exact ">3" interpretation

---

### Experiment 07: Chimeric-Only Removal
**Status**: ğŸ“‹ Planned
**Hypothesis**: Novo removed ALL chimeric antibodies regardless of other QC
**Method**:
  1. Start with 116 ELISA-only
  2. Remove all chimeric antibodies (11 total from our analysis)
  3. See resulting distribution
  4. Adjust to reach 86

**Chimeric antibodies** (11 from our analysis):
  - muromonab, cetuximab, basiliximab, infliximab
  - rituximab, alemtuzumab, bevacizumab, panitumumab
  - girentuximab, trastuzumab, gemtuzumab

**Expected**: 105 antibodies â†’ need to remove 19 more
**Script**: `experiments/novo_parity/scripts/exp_07_chimeric_removal.py`
**Output**: `experiments/novo_parity/datasets/jain_exp_07_chimeric_86.csv`
**Web validation**: TODO - verify all 11 are truly chimeric (mouse/human)

---

### Experiment 08: Discontinued-Only Removal
**Status**: ğŸ“‹ Planned
**Hypothesis**: Novo removed failed/discontinued clinical trials
**Method**:
  1. Start with 116 ELISA-only
  2. Remove discontinued antibodies (11 from our list)
  3. See resulting distribution

**Discontinued antibodies** (11 from our analysis):
  - tabalumab, girentuximab, abituzumab, dalotuzumab
  - ganitumab, robatumumab, tigatuzumab, farletuzumab
  - zanolimumab, (others TBD)

**Expected**: 105 antibodies â†’ need to remove 19 more
**Script**: `experiments/novo_parity/scripts/exp_08_discontinued_removal.py`
**Output**: `experiments/novo_parity/datasets/jain_exp_08_discontinued_86.csv`
**Web validation**: TODO - verify discontinued status for each

---

### Experiment 09: Combined QC (Chimeric + Discontinued + Outliers)
**Status**: ğŸ“‹ Planned
**Hypothesis**: Novo applied multiple QC criteria simultaneously
**Method**:
  1. Start with 116 ELISA-only
  2. Remove chimeric (11)
  3. Remove discontinued (11, some overlap)
  4. Remove VH outliers (3)
  5. Remove charge outliers (2)
  6. See if this naturally hits 86

**Expected**: Likely removes more than 30, need to be selective
**Script**: `experiments/novo_parity/scripts/exp_09_combined_qc.py`
**Output**: `experiments/novo_parity/datasets/jain_exp_09_combined_86.csv`
**Web validation**: N/A (combination of previous validations)

---

### Experiment 10: Top-30 Specific by Risk Score
**Status**: ğŸ“‹ Planned
**Hypothesis**: Remove the 30 "riskiest" specific antibodies by composite score
**Method**:
  1. Start with 116 ELISA-only (94 spec / 22 nonspec)
  2. Score each specific antibody by: chimeric + discontinued + |VH_z| + |charge_z| + outlier_hits
  3. Remove top 30 specific by score
  4. Reclassify 5 ELISA=0 â†’ nonspec to hit 27
  5. Final: 59 spec / 27 nonspec = 86

**Expected**: 59 specific / 27 non-specific = 86 total
**Script**: `experiments/novo_parity/scripts/exp_10_risk_score.py`
**Output**: `experiments/novo_parity/datasets/jain_exp_10_risk_score_86.csv`
**Web validation**: N/A (composite scoring)

---

### Experiment 11: [RESERVED FOR WEB SEARCH INSIGHTS]
**Status**: ğŸ’¡ TBD based on web search findings
**Hypothesis**: TBD after searching the 7 reclass candidates
**Method**: TBD
**Script**: TBD
**Output**: TBD
**Web validation**: Primary driver for this experiment

---

### Experiment 12: [RESERVED]
**Status**: ğŸ’¡ TBD
**Hypothesis**: TBD

---

## ğŸ” WEB SEARCH VALIDATION QUEUE

### Priority 1: The 7 Reclassification Candidates
Need to search for polyreactivity, aggregation, clinical issues:
- [ ] bimagrumab
- [ ] atezolizumab
- [ ] eldelumab
- [ ] glembatumumab
- [ ] infliximab
- [ ] rilotumumab
- [ ] seribantumab

### Priority 2: Assistant's 7 Parity Flips
Need to validate why these were chosen:
- [ ] ganitumab
- [ ] gemtuzumab
- [ ] panitumumab
- [ ] tigatuzumab
- [ ] girentuximab
- [ ] efalizumab
- [ ] zanolimumab

### Priority 3: Chimeric Antibodies
Verify all 11 are truly chimeric:
- [ ] muromonab, cetuximab, basiliximab, infliximab
- [ ] rituximab, alemtuzumab, bevacizumab, panitumumab
- [ ] girentuximab, trastuzumab, gemtuzumab

### Priority 4: Discontinued Antibodies
Verify clinical trial failures:
- [ ] tabalumab, girentuximab, abituzumab, dalotuzumab
- [ ] ganitumab, robatumumab, tigatuzumab, farletuzumab
- [ ] zanolimumab

---

## ğŸ”¬ WEB SEARCH FINDINGS

**Date**: 2025-11-03
**Search Query**: Polyreactivity, aggregation, off-target binding, biophysical issues, immunogenicity
**Results**: **2/7 candidates have STRONG evidence** for reclassification

### âœ… STRONG EVIDENCE FOR RECLASSIFICATION (2/7)

#### 1. **atezolizumab** - Aggregation-Prone, Non-Trivial Immunogenicity
**Evidence**:
- **Aglycosylated design (N297A mutation)** â†’ eliminates Fc function BUT creates stability problems
- **Unstable thermal profile**: Tm1 â‰ˆ 63.6Â°C, Tagg â‰ˆ 60.7Â°C (low for therapeutic antibody)
- **Aggregation-prone**: Engineering work on "Maxatezo" explicitly reports aglycosylated atezolizumab is unstable and prone to aggregation
- **ADA rates**: ~30% in OAK NSCLC study; 13-36% across studies (assay-dependent per FDA labeling)
- **Non-trivial but variable**: ADA incidence varies by trial, not uniformly "high"

**Sources**:
- Nature Scientific Reports (2021): Glycosylated variant improves stability vs aglycosylated form
- FDA labeling: 30% ADA in OAK trial, 13-36% range across studies
- Structural studies show large buried surface area (>2000 Ã…Â²)

**Verdict**: âœ… **CONFIRMED candidate for reclassification** - aggregation tendency + non-trivial ADA despite ELISA=0

---

#### 2. **infliximab** - High Immunogenicity, Aggregation Issues
**Evidence**:
- **61% ADA rate**: Classic NEJM Crohn's cohort showed 61% developed anti-infliximab antibodies, with shorter response duration and more infusion reactions
- **Chimeric antibody** (mouse/human) â†’ inherently more immunogenic
- **Aggregates drive CD4+ T-cell activation**: Heat-stressed infliximab aggregates drive extended CD4+ T-cell responses in vitro
  - Aggregates expose larger array of T-cell epitopes across entire variable regions
  - Even mild-condition aggregates induce higher frequency CD4 T-cell response vs native
- **Immune complex formation**: IFXâ€“TNF immune complexes show Fc-dependent uptake; TNF trimer stabilization documented
- **Anti-drug antibodies neutralize binding** â†’ enables TNF-Î± pro-inflammatory effects
- **Associated with allergic reactions and loss of response**

**Sources**:
- NEJM (2003): 61% ADA in Crohn's disease cohort
- Frontiers Immunology (2020): Aggregate-induced T-cell activation
- Multiple studies on immune complex formation and multimeric target binding

**Verdict**: âœ… **CONFIRMED candidate for reclassification** - high ADA rate + aggregate-driven immunogenicity

---

### âŒ NO PUBLIC PSR/BVP EVIDENCE (5/7)

**Framing**: These antibodies failed for efficacy or clinical safety reasons, NOT developability flags. No public polyreactivity (PSR) or biophysical property (BVP) red flags documented.

#### 3. **bimagrumab** - Clinical Efficacy Failure, Well-Tolerated
**Evidence**:
- sIBM trials: well-tolerated, no functional benefit
- Obesity studies: show fat-mass loss with preserved/increased lean mass
- **Safety profile**: Good - well tolerated up to 2 years
- **No public PSR/BVP red flags**
- Later got FDA Breakthrough Therapy designation (still in development)

**Verdict**: âŒ **NO polyreactivity evidence** - failed for efficacy, not biophysics

---

#### 4. **eldelumab** - Phase 2 UC/CD, Limited/Mixed Efficacy
**Evidence**:
- Phase 2 UC/CD: primary endpoint not achieved
- **Safety profile**: Generally acceptable safety
- **No immunogenicity observed** in trials
- **No public polyreactivity evidence**

**Verdict**: âŒ **NO polyreactivity evidence** - failed for efficacy, not biophysics

---

#### 5. **glembatumumab vedotin** - METRIC Phase 2b PFS Failure
**Evidence**:
- METRIC Phase 2b failed PFS primary endpoint
- No developability/aggregation signal publicly reported
- ADC safety profile generally acceptable
- **No public PSR/BVP red flags**

**Verdict**: âŒ **NO polyreactivity evidence** - failed for efficacy, not biophysics

---

#### 6. **rilotumumab** - Phase 3 Safety Signal (Excess Deaths)
**Evidence**:
- Phase 3 terminated for excess deaths vs control
- **Safety signal**: Mechanism-related, not polyreactivity
- HGF/MET pathway toxicity
- **No public PSR/BVP red flags**

**Verdict**: âŒ **NO polyreactivity evidence** - safety signal is mechanism-based, not biophysics

---

#### 7. **seribantumab** - Mixed Trials, NRG1+ Programs Show Response
**Evidence**:
- Older trials mixed efficacy
- NRG1-fusion programs now show responses with manageable safety
- **No public PSR/BVP red flags**
- Development continues in select indications

**Verdict**: âŒ **NO polyreactivity evidence** - no developability issues documented

---

### ğŸ“Š SUMMARY: Web Search Results

| Antibody | ELISA | total_flags | Biophysical Issues? | Reclassification? |
|----------|-------|-------------|---------------------|-------------------|
| **atezolizumab** | 0 | 3 | âœ… Aggregation + High ADA | âœ… **YES** |
| **infliximab** | 0 | 3 | âœ… 61% ADA + Aggregation | âœ… **YES** |
| bimagrumab | 0 | 4 | âŒ Efficacy failure only | âŒ NO |
| eldelumab | 0 | 3 | âŒ Efficacy failure only | âŒ NO |
| glembatumumab | 0 | 3 | âŒ Efficacy failure only | âŒ NO |
| rilotumumab | 0 | 3 | âŒ Mechanism toxicity | âŒ NO |
| seribantumab | 0 | 3 | âŒ Efficacy failure only | âŒ NO |

**Key Finding**: Only **2/7 candidates** have published PSR/BVP evidence justifying reclassification from specific â†’ non-specific. The other 5 failed for efficacy or mechanism-related safety, NOT developability flags.

---

### ğŸ§  IMPLICATIONS FOR EXPERIMENT DESIGN

**Original Hypothesis** (Exp 05):
- Reclassify 5 of these 7 from ELISA=0 â†’ non-specific based on total_flagsâ‰¥3
- **Problem**: Only 2/7 have public PSR/BVP justification!

**Honest Framing Options**:
1. **Evidence-based (2 only)**: atezolizumab + infliximab
   - Results in 62/24 split (not 59/27)
   - Most scientifically rigorous

2. **Parity levers (use 5 including 3 without evidence)**:
   - Explicitly document that 3 have "no public PSR/BVP evidenceâ€”used only as parity levers"
   - Acknowledge this is a methodological choice to match Novo's distribution
   - Less defensible scientifically

3. **Search for OTHER ELISA=0 antibodies** with total_flagsâ‰¥3:
   - May find better-justified candidates in the 116 set
   - Need to scan full dataset

**Next Action**: Search the 116 set for OTHER ELISA=0 antibodies with total_flagsâ‰¥3 to find 3 more candidates with potential justification

---

## ğŸ”¬ BREAKTHROUGH: JAIN 2017 PNAS SUPPLEMENTAL DATA

**Date**: 2025-11-03
**Discovery**: Converted raw Jain PNAS .xlsx files (SD01, SD02, SD03) to CSV and found **actual biophysical measurements**!

### ğŸ“Š SD03 Contains Gold Standard Biophysical Assays:

**Key Columns**:
- **PSR (Poly-Specificity Reagent)**: 0-1 score, >0.4 = high polyreactivity
- **AC-SINS (Affinity-Capture Self-Interaction Nanoparticle Spectroscopy)**: âˆ†Î»max (nm), >20 = strong self-interaction/aggregation
- **HIC Retention Time**: Hydrophobic interaction chromatography, >10 min = hydrophobic
- **Fab Tm by DSF**: Thermal stability, <65Â°C = unstable
- **SGAC-SINS**: Salt-gradient aggregation propensity
- **ELISA**: Raw ELISA OD values (not just 0-6 flags!)
- **BVP ELISA**: Baculovirus particle ELISA (orthogonal polyreactivity assay)

### ğŸ§ª Research Logic: ELISA First, Then Biophysics QC

**What Novo LIKELY Did (Industry Standard Workflow)**:

```
Step 1: ELISA Primary Filter
  137 total â†’ Remove mild (ELISA 1-3) â†’ 116 (94 spec / 22 nonspec)

Step 2: Biophysical QC (Secondary/Confirmatory)
  116 â†’ Calculate composite risk from PSR + AC-SINS + HIC + Tm
       â†’ Remove/reclassify high-risk antibodies â†’ 86 (59 spec / 27 nonspec)
```

**Why this makes sense**:
- ELISA is PRIMARY polyreactivity assay (most sensitive)
- PSR, AC-SINS, HIC are SECONDARY/orthogonal confirmatory assays
- Standard pharma workflow: categorize first, then apply developability filters
- Composite risk scoring is industry best practice (multiple orthogonal measurements)

---

### ğŸ“Š Biophysical Data Analysis: The 116 ELISA-Only Set

**High PSR (>0.4) in our 116 set:**

| Antibody | Label | ELISA | PSR Score | Notes |
|----------|-------|-------|-----------|-------|
| ixekizumab | 1 (nonspec) | 6 | 0.810 | Already caught by ELISA âœ… |
| bococizumab | 1 (nonspec) | 6 | 0.760 | Known failure case, ELISA caught it âœ… |
| bimagrumab | 0 (spec) | 0 | 0.697 | âš ï¸ ELISA missed it! |
| cixutumumab | 1 (nonspec) | 6 | 0.657 | ELISA caught it âœ… |
| lenzilumab | 1 (nonspec) | 6 | 0.655 | ELISA caught it âœ… |
| emibetuzumab | 1 (nonspec) | 6 | 0.643 | ELISA caught it âœ… |
| bavituximab | 0 (spec) | 0 | 0.557 | âš ï¸ ELISA missed it! |
| briakinumab | 1 (nonspec) | 4 | 0.556 | ELISA caught it âœ… |
| ganitumab | 0 (spec) | 0 | 0.553 | âš ï¸ ELISA missed it! |
| gantenerumab | 1 (nonspec) | 6 | 0.553 | ELISA caught it âœ… |
| patritumab | 1 (nonspec) | 4 | 0.520 | ELISA caught it âœ… |
| olaratumab | 0 (spec) | 0 | 0.483 | âš ï¸ ELISA missed it! |

**Key Finding**: 8/12 high-PSR antibodies were correctly caught by ELISA. But **4 specific antibodies have PSR >0.4 despite ELISA=0**!

**The 4 ELISA-discordant cases:**
1. bimagrumab (PSR=0.697, total_flags=4)
2. bavituximab (PSR=0.557, total_flags=2)
3. ganitumab (PSR=0.553, total_flags=2)
4. olaratumab (PSR=0.483, total_flags=2)

---

### ğŸ§® Composite Biophysical Risk Scoring

**Formula**: Risk = PSR_norm + AC-SINS_norm + HIC_norm + (1 - Tm_norm)

Each metric normalized 0-1 within the 94 specific antibodies, then summed.

**Top 10 Riskiest Specific Antibodies** (from 116 set):

| Rank | Antibody | Risk Score | PSR | AC-SINS | HIC | Tm | Notes |
|------|----------|------------|-----|---------|-----|----|-------|
| 1 | bavituximab | 2.74 | 0.557 | Extreme | High | 59.5Â°C | All metrics bad |
| 2 | lirilumab | 2.57 | 0.183 | High | Extreme | 69.0Â°C | HIC retention problem |
| 3 | bimagrumab | 2.40 | 0.697 | Extreme | Med | 72.0Â°C | PSR + AC-SINS |
| 4 | basiliximab | 2.40 | 0.397 | Extreme | Low | 60.5Â°C | AC-SINS + low Tm |
| 5 | glembatumumab | 2.11 | 0.166 | Extreme | High | 72.0Â°C | AC-SINS + HIC |
| 6 | urelumab | 1.95 | 0.0 | Extreme | Med | 74.5Â°C | AC-SINS only |
| 7 | infliximab | 1.95 | 0.0 | Extreme | Med | 81.5Â°C | AC-SINS (+ 61% ADA!) |
| 8 | drozitumab | 1.93 | 0.0 | Extreme | Low | 68.0Â°C | AC-SINS only |
| 9 | tremelimumab | 1.84 | 0.145 | Extreme | High | 71.5Â°C | AC-SINS + HIC |
| 10 | nimotuzumab | 1.83 | 0.0 | Low | Extreme | 68.5Â°C | HIC retention problem |

**Notable**: Infliximab (#7) has high composite risk + literature evidence (61% ADA, aggregation). Atezolizumab is #13 with known aggregation issues.

---

### ğŸ¯ Hypothesis: Composite Risk Threshold for 116â†’86

**Math Requirements**:
- Start: 94 specific + 22 non-specific = 116
- Target: 59 specific + 27 non-specific = 86
- Need: Remove 35 specific, add 5 non-specific (net: -30 antibodies)

**Approach**:
1. **Reclassify 4-5 high-PSR specific â†’ non-specific** (ELISA discordant cases)
   - bimagrumab, bavituximab, ganitumab, olaratumab
   - Plus 1 more: infliximab or atezolizumab?

2. **Remove top 30-35 by composite risk**
   - Use composite risk threshold to identify developability failures
   - Orthogonal biophysical evidence trumps ELISA=0

---

### ğŸ§ª Experiments to Test (Using Real Biophysics)

**Experiment 11**: PSR Threshold Reclassification
- Reclassify all ELISA=0 with PSR >0.4 â†’ non-specific
- See if this explains the +5 non-specific shift

**Experiment 12**: Composite Risk Top-35 Removal
- Remove top 35 specific antibodies by composite risk score
- Check if remaining distribution matches 59/27

**Experiment 13**: Combined PSR + Risk Removal
- Reclassify 4 PSR-discordant â†’ non-specific
- Remove next 30-31 by composite risk
- Should yield 59/27 exactly

**Experiment 14**: Sensitivity Analysis
- Vary PSR threshold (0.3, 0.4, 0.5, 0.6)
- Vary risk threshold
- Find optimal combination that hits 59/27

---

## ğŸ“Š RESULTS TRACKING

### Confusion Matrix Comparison Template

**Target (Novo's reported)**:
```
                Predicted
              Spec | Nonspec
Actual   â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€
Spec        40    |   19      (59 total)
Nonspec     10    |   17      (27 total)

Accuracy: 66.28% (57/86)
```

**Experiment N**:
```
                Predicted
              Spec | Nonspec
Actual   â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€
Spec        ??    |   ??      (?? total)
Nonspec     ??    |   ??      (?? total)

Accuracy: ??.??% (??/??)
Delta: Â±?.??%
```

### Results Summary Table

| Exp | Description | Size | Spec/Nonspec | Accuracy | Î” Novo | Status |
|-----|-------------|------|--------------|----------|--------|--------|
| 01  | Baseline    | 116  | 94/22        | N/A      | N/A    | ğŸ“‹ Planned |
| 02  | Biology QC  | 86   | 66/20        | TBD      | TBD    | ğŸ“‹ Planned |
| 03  | Parity Shim | 86   | 59/27        | TBD      | TBD    | ğŸ“‹ Planned |
| 04  | Z-score QC  | 92   | 73/19        | TBD      | TBD    | ğŸ“‹ Planned |
| 05  | Reclass+Rem | 86   | 59/27        | TBD      | TBD    | ğŸ“‹ Planned |
| 06  | Threshold 3 | 86?  | ?/?          | TBD      | TBD    | ğŸ“‹ Planned |
| 07  | Chimeric    | 86   | ?/?          | TBD      | TBD    | ğŸ“‹ Planned |
| 08  | Discontinue | 86   | ?/?          | TBD      | TBD    | ğŸ“‹ Planned |
| 09  | Combined QC | 86   | ?/?          | TBD      | TBD    | ğŸ“‹ Planned |
| 10  | Risk Score  | 86   | 59/27        | TBD      | TBD    | ğŸ“‹ Planned |

---

## ğŸ”— PROVENANCE CHAIN

### Input Files
- `test_datasets/jain_ELISA_ONLY_116.csv` (SSOT: 116 antibodies, 94 spec / 22 nonspec)
- `test_datasets/jain/jain_116_qc_candidates.csv` (24 QC candidates from z-score analysis)
- `test_datasets/jain/jain_ELISA_ONLY_116_with_zscores.csv` (with all features)

### Generated Files
Each experiment generates:
1. **Dataset CSV**: `experiments/novo_parity/datasets/jain_exp_{N}_{desc}_{size}.csv`
2. **Audit log**: `experiments/novo_parity/results/exp_{N}_audit.json`
3. **Confusion matrix**: `experiments/novo_parity/results/exp_{N}_confusion_matrix.txt`
4. **Inference results**: `experiments/novo_parity/results/exp_{N}_results.json`

### Audit Log Schema
```json
{
  "experiment_id": "exp_01",
  "timestamp": "2025-11-03T21:45:00Z",
  "script": "experiments/novo_parity/scripts/exp_01_baseline.py",
  "input_files": ["test_datasets/jain_ELISA_ONLY_116.csv"],
  "output_file": "experiments/novo_parity/datasets/jain_exp_01_baseline_116.csv",
  "method": "Baseline count, no modifications",
  "removed_ids": [],
  "reclassified_ids": [],
  "final_counts": {
    "total": 116,
    "specific": 94,
    "non_specific": 22
  },
  "parameters": {},
  "notes": "Sanity check - verify starting distribution"
}
```

---

## ğŸš€ EXECUTION PLAN

### Phase 1: Setup & Baseline (Today)
1. âœ… Create branch `ray/novo-parity-experiments`
2. âœ… Create directory structure
3. âœ… Create this planning document
4. â¸ï¸ Write baseline script (Exp 01)
5. â¸ï¸ Begin web search validation

### Phase 2: Core Experiments (Next)
1. â¸ï¸ Implement Exp 02-05 (the main hypotheses)
2. â¸ï¸ Run inference on each
3. â¸ï¸ Compare confusion matrices
4. â¸ï¸ Document findings

### Phase 3: Alternative Hypotheses (If needed)
1. â¸ï¸ Implement Exp 06-10 based on Phase 2 insights
2. â¸ï¸ Run inference
3. â¸ï¸ Identify best match (if any)

### Phase 4: Documentation & Decision (Final)
1. â¸ï¸ Update `EXPERIMENTS_LOG.md` with all results
2. â¸ï¸ Choose primary test set for paper
3. â¸ï¸ Merge or document experimentation branch
4. â¸ï¸ Email Max with findings

---

## ğŸ“ RUNNING LOG

### 2025-11-03 21:45 - Branch Created
- Created `ray/novo-parity-experiments` branch
- Set up directory structure
- Created master planning document
- Ready for experimentation

**Next**: Begin web search validation of the 7 reclassification candidates

---

## âœ… ACCEPTANCE CRITERIA

**Success is NOT matching Novo exactly!**

Success is:
1. âœ… Full traceability (every CSV has a script, every script has provenance)
2. âœ… Understanding the space of possibilities
3. âœ… Documenting what DOESN'T work (as valuable as what does)
4. âœ… Having defensible test sets for inference
5. âœ… Being transparent about methodology

**Primary test set remains**: 116 ELISA-only antibodies (method-faithful)
**Secondary exploration**: Which permutations get close to Novo's 59/27?

---

## ğŸ¯ KEY PRINCIPLES

1. **No slop** - Every file is traceable to a script
2. **Reproducible** - Anyone can re-run the experiments
3. **Transparent** - Document what fails, not just what succeeds
4. **Iterative** - Update this plan as we learn from web search
5. **Principled** - No arbitrary choices without documented rationale

---

**This is a living document - update as experiments run!**
